Last reviewed · How we verify

NCT03800017

Skeletal Muscle Function in Interstitial Lung Disease

Recruiting now NA Last updated 16 January 2025
What this trial tests

NA trial testing Hyperoxia in Interstitial Lung Disease in 40 participants. Currently enrolling.

Timeline
7 August 2024
Primary endpoint
31 December 2026
31 December 2026

Quick facts

Lead sponsorUniversity of British Columbia
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingsingle
Primary purposebasic science
Enrollment40
Start date7 August 2024
Primary completion31 December 2026
Estimated completion31 December 2026
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

University of British Columbia

Who can join

Adults 40 to 80, any sex, with Interstitial Lung Disease or Idiopathic Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i) examine differences in the structure and function of the leg muscles in ILD patients, ii) determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients with ILD, and iii) determine the effects of breathing extra oxygen on leg muscle fatigue, as well as ability to exercise in ILD patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Hyperoxia

Trials testing the same drug.

Other recruiting trials for Interstitial Lung Disease

Currently open trials in the same condition.

Other University of British Columbia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03800017.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing